Journals / Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi / 2019 / Cilt: 33 - Sayı: 3

Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study

Kronik Hepatit B Hastalarında Delta Hepatit Seroprevalansı: Tek Merkez Çalısması

Pages
137–141
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Cirrhotic patients were found to have 11-fold higher presence of HDV compared to non-cirrhotic patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Hepatitis B virus (HBV) infection is an important health problem in Turkey.
📊
Key Findings & Data:Mortality and morbidity rates arise by accompanion of Hepatitis D infection (HDV).
💡
Conclusion & Impact:Conclusion: Cirrhotic patients were found to have 11-fold higher presence of HDV compared to non-cirrhotic patients.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Hepatitis B virus (HBV) infection is an important health problem in Turkey. Mortality and morbidity rates arise by accompanion of Hepatitis D infection (HDV). Prevalence of Hepatitis Delta virus (HDV) in HBV-positive individuals varies according to the regions in Turkey with 20% occurence in the western and up to 46% in the eastern parts. The aim of this study is to assess the presence of HDV in HBV patients applying to the center of our study. Materials and Methods: A total of 1025 patient records were reviewed retrospectively. Eighty-four were excluded due to insufficient case data; the remaining 941 patients were included in the review process. Patients were divided into those with chronic hepatitis B (group A) and those with liver cirrhosis (group B). HDV presence in both groups was assessed and compared between each group. Results: Of all 941 patients included in the study, 857 (91%) had chronic hepatitis B (Group A) and 84 (9%) had liver cirrhosis (Group B). Among group A patients, 62% were male and 38% were women; average age was 42±13 years. Group B patients were 77% male and 23% female; mean age was 54±14 years. Among all patients, HDV seropositivity was 3.4%, with 1.8% among group A patients and 20% in Group B (P= 0.001). Results were assessed by Chi-Square test and t–test. Group B patients were found to have significantly higher age (P= 0.007) and HDV seropositivity (P= 0.004) compared to group A patients. Conclusion: Cirrhotic patients were found to have 11-fold higher presence of HDV compared to non-cirrhotic patients.

Özet

Amaç: Hepatit B virüs (HBV) infeksiyonu Türkiye’de önemli bir sağlık problemidir ve Hepatitis D infeksiyonu (HDV) ile birlikte olması ile mortalite ve morbidite artmaktadır. HDV prevelansı Türkiye’nin batı bölgesinde %20 iken Doğu Anadolu Bölgesinde %46 olarak farklılıklar göstermektedir. Bu çalışmanın amacı hastanemize gelen HBV hastalarındaki HDV seroprevalansı saptamaktır. Gereç ve Yöntem: Toplam 1025 hastanın kayıtları retrospektif olarak incelendi. 84 kişinin verileri yetersiz olduğundan dışlandı. Kalan 941 hastaya ait kayıtlar değerlendirildi. Hastalar Kronik Hepatit B (Group A) ve Siroz (Group B) olarak ayrıldı. Her iki grup arasında HDV infeksiyonunun bulunması açısından karşılaştırma yapıldı. Bulgular: 941 hastanın 857’si (%91) kronik Hepatit B (Grup A), 84’ü (%9) sirotik (Grup B) idi. Grup A daki hastların %62’si erkek, %38’i kadın olup yaş ortalaması 42±13 yıldı. Grup B deki hastaların %77’si erkek ve %23’ü bayan olup yaş ortalaması 54±14 yıldı. Grup B de yaş ortalaması daha yüksekdi (P= 0.015) Total hastalarda HDV seropozitifliği %3.4 olup, Grup A da %1.8, Grup B de %20 idi, Grup B de HDV pozitifliği yüksekti (P= 0.001). Sonuçlar ki kare ve t test ile değerlendirildi. Her iki grupta da erkek cinsiyet olması kadın cinsiyet olmasına göre daha yüksek oranda görüldü (Grup A da P= 0.007, Group B de P= 0.004) Sonuçlar istatistiksel olarak alamlı bulundu. Sonuç: Çalışmaya katılan tüm hastlarda %3.4 oranında HDV seropozitifliğ saptanmıştır. Sirotik hastlarda ise (%20), kronik hepatit B (%1.8) hastalarından 11 kattır.

🔖

Cite This Article

VATANSEVER, S., SERİN, A. (2022). Seroprevalence of Delta Hepatitis in Chronic Hepatitis B Patients: Single Center Study. Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi, Cilt: 33 - Sayı: 3, 137–141. https://ajindex.com/articles/650604

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Rizzetto M, Canese MG, Arico J, et al. Immunofluorescence detection of a new antigen–antibody system associated to the hepatitis B virus in the liver and in the serum of HBsAg carriers. Gut 1977; 18: 997-1003
  2. Rizzetto M, Canese MG, Gerin JL, et al. Transmission of the hepatitis B virus-associated δ antigen to chimpanzees. J Infect Dis 1980; 141: 590-602
  3. Taylor JM, Farci P, Purcell RH. Hepatitis D (δ) virus. In: Knipe DM, (Editor). Fields Virology. PA, USA: Lippincott Williams & Wilkins, 2007: 3031-3046
  4. Sureau C, Negro F. The hepatitis delta virus: Replication and pathogenesis. J Hepatol 2016; 64: S102–S116
  5. Jardi R, Buti M, Rodriguez-Frias F, et al. Clinical significance of two forms of IgM antibody to hepatitis delta virus. Hepatology 1991; 14: 24-28
  6. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: Update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7: 31-40
  7. Mansour W, Ducancelle A, Le Gal F, et al. Resolution of chronic hepatitis delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine. J Clin Virol 2010; 47: 97-99
  8. Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat 2010; 17: 749-756 9. Wedemeyer H, Yurdaydìn C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364: 322-331
  9. MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harbor perspectives in medicine 2015; 5: a021410
  10. Deny P. Hepatitis δ virus genetic variability: From genotypes I, II, III to eight major clades. Curr Top Microbiol Immunol 2006; 307: 151-171
  11. Hadler SC, Monzon M, Bensabath G. Epidemiology of hepatitis delta virus infection in less developed countries. Progr Clin Biol Res 1991; 364: 21-31
  12. Hadler SC, Fields HA. Hepatitis delta virus. In: Belshe RB (Editor). Textbook of human virology. 2nd Edition, St. Louis, London: The CV Mosby Co, 1991: 749-766
  13. Polish LB Gallagher M, Fields HA, Hadler SC. Delta hepatitis: Molecular biology and clinical and epidemiological features. Clin Microbiol Rev 1993; 6: 211229
  14. World Health Organization. “Hepatitis Delta”. http:// www.searo.who.int/EN/Section10/Section1027_9489.htm/ 05.06.2018
  15. Fonseca JC. Hepatitis D. Rev Soc Bras Med Trop 2002; 35: 181-190
  16. Uzun B, Şener AG, Güngör S, Afşar I, Demirci M. Evaluation of hepatitis delta virus (HDV) infection in blood donors